OPKO Health (NASDAQ:OPK) Given Buy Rating at HC Wainwright

OPKO Health (NASDAQ:OPK)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $3.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 64.84% from the company’s current price. HC Wainwright also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.30) EPS.

A number of other research firms also recently weighed in on OPK. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Trading Down 2.2 %

Shares of NASDAQ OPK opened at $1.82 on Wednesday. OPKO Health has a 1-year low of $0.89 and a 1-year high of $2.04. The company has a market cap of $1.22 billion, a PE ratio of -9.58 and a beta of 1.70. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a 50-day moving average of $1.65 and a two-hundred day moving average of $1.57.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. As a group, equities analysts expect that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the acquisition, the chief executive officer now owns 213,186,477 shares in the company, valued at $313,384,121.19. This trade represents a 0.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders acquired a total of 964,971 shares of company stock valued at $1,493,692 over the last ninety days. Insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Intech Investment Management LLC acquired a new position in shares of OPKO Health in the third quarter valued at approximately $190,000. Integrated Investment Consultants LLC acquired a new position in shares of OPKO Health in the third quarter valued at approximately $233,000. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 217,450 shares during the period. Finally, Rubric Capital Management LP boosted its holdings in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.